Hong‐Hong Yan

Abstract PS5-02-16: Clinical outcomes and treatment attrition rates of HER2 positive metastatic breast cancer (MBC) patients at a tertiary referral cancer centre in London: the Guy’s Cancer experience

Hong‐Hong Yan, M. Toki, Hartmut Kristeleit

Abstract Background: Treatment options for HER2 positive MBC are increasing and trastuzumab deruxtecan (T-DXd) is now used in earlier lines of treatment, having shown superiority to trastuzumab emtansine (T-DM1) in DESTINY-Breast03 and to THP in DESTINY-Breast09. Uncertainty remains on the optimal sequencing …

gb (code pays fourni par la source)

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

Hong‐Hong Yan, Xin Li Huang, Ping Wu, Chengxin Deng et autres

BACKGROUND: Induction therapy is the first critical step in the overall treatment of Acute myeloid leukemia (AML). The "3 + 7" regimen remains the backbone treatment for newly diagnosed AML patients suitable for intense chemotherapy (IC). However, its efficacy, toxicity, high complications …

cn (code pays fourni par la source)

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases

Yang-Si Li, Wenpu Lai, Kai Yin, Hai‐Yan Tu et autres

Background Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers …

cn, hk (code pays fourni par la source)

25P Reflex molecular biomarker testing in colorectal cancer: Pathway insights from the South-East England network

W.K. Liu, Durga V. Sritharan, Roger Cox, Vijay Jeyachandran et autres

gb (code pays fourni par la source)

Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.

SiYang Maggie Liu, Song Dong, Xue‐Ning Yang, Ri-Qiang Liao et autres

8025 Background: Previously, we reported the clinical findings of stage-one enrollment from a phase II trial of neoadjuvant immunochemotherapy (IO) in untreated patients with resectable non-small cell lung cancer (NSCLC) (CTONG1804, NCT04015778). Recently, two-stage enrollment has been completed. This trial provided an …

cn (code pays fourni par la source)

Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.

Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.

Supplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S1. Performance Metrics of Landmark and Longitudinal MRD Analyses Stratified by Tumor Type.

Supplementary Figure S3 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Supplementary Figure S3. (A) Kaplan–Meier analysis of disease-free survival (DFS) stratified by landmark MRD status for LUAD patients. (B) Kaplan–Meier analysis of DFS stratified by longitudinal MRD status for LUAD patients. (C) Kaplan-Meier analysis of the survival time since last blood, comparing …

Supplementary Figure S7 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Supplementary Figure S7. Univariate cox analysis of MRD lead time with ctDNA level and maxVAF, as continuous variables

Supplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Supplementary Figure S4. Kaplan-Meier analysis of the survival time since last blood, comparing patients with longitudinal undetectable MRD to those with longitudinal detectable MRD (last blood draw positive), excluding synchronous recurrences.

Supplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Supplementary Figure S5. CT and MRI images of patients with brain-only metastases who had longitudinal undetectable MRD. The red arrows indicate the location of metastatic lesions.